Suchergebnisse - "Xu, Binghe"

PubPharm (41)

1

Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer : A prospective study

enthalten in: Thoracic cancer | 2024

von Wu, Y. | Mo, H. | Xu, H. | +4

2

OlympiAD extended follow-up for overall survival and safety : Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Robson, M. | Im, S. | Senkus, E. | +10

3

Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Wang, J. | Cai, L. | Song, Y. | +13

4

Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node-Positive Breast Cancer : A Randomized Clinical Trial

enthalten in: JAMA network open | 2023

von Yuan, P. | Kang, Y. | Ma, F. | +8

5

Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer : Primary results from PALOMA-4

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Xu, B. | Hu, X. | Li, W. | +15

6

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Cortés, J. | Kim, S. | Chung, W. | +122

CommentIn: Nat Rev Clin Oncol. 2022 May;19(5):283. - PMID 35361895

7

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer : a randomized, phase 3 trial

enthalten in: Nature medicine | 2021

von Xu, B. | Zhang, Q. | Zhang, P. | +24

CommentIn: Nat Med. 2021 Nov;27(11):1868-1869. - PMID 34750558

8

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer : a meta-analysis and systemic review of randomized clinical trials

enthalten in: Frontiers of medicine | 2021

von Zhu, W. | Xu, B.

9

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE) : a multicentre, open-label, randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Xu, B. | Yan, M. | Ma, F. | +31

10

Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer : a systematic review and network meta-analysis

enthalten in: Current problems in cancer | 2020

von Han, Y. | Wang, J. | Wang, Z. | +1

1
2
3
4
5
Nächster »
[5]